top of page

HekaBio enters License Agreement with Orgenesis

HekaBio K.K. has entered into a License Agreement with Orgenesis Inc. (NASDAQ: ORGS), a manufacturer, service provider and developer of advanced cell therapies, pursuant to the Joint Venture Agreement the parties entered into on July 10, 2018. Under the License and Joint Venture Agreements, Orgenesis and HekaBio will collaborate in the clinical development and commercialization of regeneration and cell and gene therapeutic products in Japan.

Vered Caplan, CEO of Orgenesis, further commented, “We are delighted to partner with HekaBio, which has an in-depth understanding of the cell therapy environment in Japan. HekaBio specializes in product in-licensing, clinical and regulatory development, as well as commercialization, which will help facilitate our entry into the cell therapy market in Japan.”

Rob Claar, CEO, of HekaBio, commented, “We look forward to rapidly advancing the clinical and commercial development of Orgenesis’ cell therapies in the Japanese market. Orgenesis is at the forefront of the regenerative medicine industry, pioneering technologies that have broad application across many indications, including diabetes, as well as other autoimmune diseases. Japan represents a significant market opportunity for cell therapies. Importantly, Japan has a favorable regulatory environment allowing in some cases a conditional market approval following safety trials, which may help to accelerate our path to commercialization.”

About Orgenesis

Orgenesis is a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and support services. Through its Israeli subsidiary, Orgenesis Ltd., Orgenesis is developing technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs). Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. Through its Masthercell Global subsidiary, a global contract development and manufacturing organization (CDMO), Orgenesis is able to deliver optimized process industrialization capacities to cell therapy organizations and speed up the arrival of their therapies onto the market. From technology selection to business modeling, GMP manufacturing, process development, and quality management, Masthercell’s teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. Masthercell operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin. This integrated approach supports the Company's business philosophy of bringing to market significant life-improving medical treatments. For more information, visit

About Hekabio

HekaBio’s mission is to connect world-leading healthcare innovations to unmet medical needs in Japan, with broad category development expertise in pharma, medical device, diagnostics and cell & gene therapies. HekaBio targets innovations in oncology, CNS and autoimmune disease that have high potential for significant therapeutic benefit and healthcare cost reduction. For more information, visit

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended t. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, the success of our reorganized CDMO operations, the success of our partnership with Great Point Partners, our ability to achieve and maintain overall profitability, the sufficiency of working capital to realize our business plans, the development of our transdifferentiation technology as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; our technology not functioning as expected; our ability to retain key employees; our ability to satisfy the rigorous regulatory requirements for new procedures; our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended November 30, 2017, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact for HekaBio:

Mari Tanaka,

Corporate Communications 

Contact for Orgenesis:

David Waldman

Crescendo Communications, LLC

Tel: 212-671-1021



Alpha Tau Medical社、再発頭頸部癌に対するAlpha DaRTの製造販売承認申請を医薬品医療機器総合機構へ提出

参考資料 本資料は、2023年11月20日にAlpha Tau Medical社(イスラエル)が発表した英語版プレスリリースの翻訳であり、参考資料として提供するものです。正式言語は英語のため、表現や内容は英文が優先されることにご留意ください。 【イスラエル、エルサレム - 2023年11月20日】 アルファ粒子線による革新的な治療機器Alpha DaRT™の開発元であるAlpha Tau Medi


bottom of page